tbuckley/cabot-search huggingface dataset:
NIMG-70. LOCALIZATION OF ELOQUENT MOTOR CORTEX USING RESTING STATE FUNCTIONAL MRI (rsfMRI) IN PATIENTS WITH HEMIPARESIS: COMPARISON OF TEMPLATE ANATOMICAL AND FUNCTIONAL SEED
Authors: Kookjin Ahn, Yeonsoo Lee, Yong-Kil Hong, Shinsoo Jeun
Journal: Neuro-Oncology (2016)

In patients with focal mass involving motor cortex and accompanying motor disability, it is very difficult to make motor cortex map using task fMRI. Recently, resting state fMRI (rsfMRI) can be replaced in these patients with commonly used seed based technique. In this case, expected motor cortex rather than true motor cortex can be used as a seed point for contralateral motor cortex localization. The purpose of our study is to assess the usefulness of functional motor cortex uncovered by task fMRI as a seed point to localize the contralateral motor cortex in patients with hemiparesis. Eight patients with brain lesions involving motor cortex and ten volunteers were included. Task fMRI was performed with alternative fingers and toes movements and rsfMRI was acquired for 8 minutes echoplanar images. In rsfMRI, two concepts of seeds were made: anatomical seed based on the template and functional seed uncovered by task fMRI. Anatomical seed is template based seed point and functional seed is an actual, functional seed point with maximal signal on task fMRI. We compared the results from anatomical and functional seeds qualitatively. In all patients with focal mass at motor cortex and all volunteers, the motor cortex maps of rsfMRI using functional seeds showed better results than those using anatomical seeds (p < 0.01). In ten volunteers, strong correlations and close similarities were noted between the motor cortex maps from rsfMRI and task fMRI (p < 0.01). RsfMRI should be very useful to localize the motor cortex in patients with hemiparesis. Functional seed rather than anatomical seed should be more accurate in localizing the contralateral motor cortex.
A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)
Authors: Kami J. Maddocks, Jonathon B. Cohen, Beth Christian, Joseph M Flynn, Samantha M. Jaglowski, Kristie A. Blum
Journal: Blood (2014)
A Multi-Center Prospective Study Utilizing a Simplified Treatment Algorithm Complemented By Expert Support Decreases Induction Mortality and Improves Survival in Acute Promyelocytic Leukemia (APL). Results of the APL Trial in Georgia, South Carolina and Neighboring States
Authors: Anand Jillella, Prachi Karkhanis, Rashmi Sharma, Sheldon Bolds, Anima Shrestha, Kaitlin Sitchenko, Veeraen Jonnalagadda, Manila Gaddh, Leon Bernal-Mizrachi, Leonard T. Heffner, Elliott F. Winton, Morgan L. McLemore, Amelia Langston, Jacques Galipeau, Imre Bodó, Zaid Al-Kadhimi, Asad Bashey, Robert K. Stuart, Sarah I. Vidito, Asim Pati, Jonathan M. Gerber, Michael R. Grunwald, Kyle T. Bradley, Jose Tongol, Mohamed El-Geneidy, Hanna Jean Khoury, Martha Arellano, Vamsi Kota
Journal: Blood (2016)
Small Molecule ST2 Inhibitors Cause Reduction of Soluble ST2 and Improve Gvhd and Survival In Vivo
Authors: Chao-Yie Yang, Abdulraouf Ramadan, Etienne Daguindau, Jilu Zhang, Zachary Bolten, Krishnapriya Chinnaswamy, Jeanne Stuckey, Sophie Paczesny
Journal: Blood (2016)
MPTH-29. CORRESPONDENCE OF SURVIVAL CURVES BETWEEN CONVENTIONAL AND NEW DIAGNOSES ADOPTED BY THE 2016 WHO CLASSIFICATION IN 367 NEWLY DIAGNOSED GRADE 2/3 GLIOMA AT TWMU
Authors: Soko Ikuta, Takashi Maruyama, Masayuki Nitta, Takashi Komori, Saori Okamoto, Shunsuke Tuzuki, Takayuki Yasuda, Takakazu Kawamata, Yoshihiro Muragaki
Journal: Neuro-Oncology (2016)

The new WHO classification brought several changes which will lead to difficulties for evaluation in former cases. Understanding the differences and correspondences of the backgrounds between previous and new diagnoses helps to balance this issue. We show 367 newly diagnosed grade 2 (n=216) and grade 3 (n=151) glioma patients’ overall survival (OS), progression survival (PFS), and impact of radio-chemotherapy in both conventional classification and 2016 WHO classification adopted categories. Overall survival of grade 2 patients was significantly longer than grade 3 patients (10year survival rate 78.3% vs. 65.9%, p=0.0016). However there was no difference in PFS (6 .3 vs. 8.8 years). Sixty-one percent of conventional oligoastrocytoma changed into oligodendroglioma(OD) in 2016 WHO, and the rest were into diffuse astrocytoma(DA). Twenty percent of oligodendroglioma change into DA because of 1p19q deletion status, but only 4% of astrocytoma change into OD. Conventional grade 2 showed significant differentiation of OS and PFS between oligodendroglioma, oligoastrocytoma, and astrocytoma (OS p=0.0176, PFS p=0.0006), but no signification in grade 3 (OS p=0.0613, PFS p=0.3995). In contrast, those classified by 2016 WHO showed clear significances between OD, DA with IDH mutation, and DA with IDH wild type in both grade 2 and 3 (<0.0001 in all). In differentiations between grade 2 and 3, only DA with IDH wild type showed significant differentiation of OS (p=0.0353), and DA with IDH mutant showed significant differentiation of PFS (p=0.0197) with longer consequence in grade 3. The most significant differentiation of the background between grade 2 and 3 was the operation rate of radio-chemotherapy which was 98% in grade 3 and only 32% in grade 2. The new classification showed clearer differentiation between groups than the ordinary’s. Oligodendroglioma type and DA with IDH mutant can induce sensitivity to radio-chemotherapy, and extensive resection might be more effective for DA-IDH wild type.
Durable Responses with Autologous Hematopoietic Stem Cell Transplantation in Patients with POEMS Syndrome
Authors: Krina Patel, Robert Z. Orlowski, Nina Shah, Qaiser Bashir, Yvonne T Dinh, Gabriela Rondon, Sergio Giralt, Richard Champlin, Muzaffar H Qazilbash
Journal: Blood (2011)
The role of health professionals in informing patients with pulmonary diseases to stop smoking: final data of an Italian multicentric survey
Authors: S. Demichelis, S.G. Rapetti, D. Galetta, A. Catino, D. Ricci, A.M. Moretti, E. Bria, S. Pilotto, A. Bruno, G. Valmadre, G.P. Bandelli, R. Trisolini, M. Gianetta, M.V. Pacchiana, S. Vallone, S. Novello
Journal: Annals of Oncology (2016)
A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
Authors: M. Hansen, P. Gimsing, A. Rasmussen, P. Buhl Jensen, L. Meldgaard Knudsen
Journal: Journal of Clinical Oncology (2005)

3137 Background PXD101 is a novel hydroxamate HDAC inhibitor with potent antiproliferative activity in vitro against many different neoplastic cell lines including myeloma and leukemia/ lymphoma lines. PXD101 inhibits tumor growth in vivo in pre-clinical models and is generally well tolerated. A phase 1 trial of intravenous PXD101 treatment in patients with advanced solid tumors proved PXD101 to be clinically well tolerated at doses leading to prolonged pharmacodynamic effects such as acetylation of circulating white blood cells. We now present a Phase 1 trial of PXD101 in patients with advanced hematological tumors refractory to standard therapy. Objective The objective of this study is to determine the maximum tolerated dose (MTD) of PXD101 administered as a 30-minute IV infusion on days 1 to 5 of a 21 days cycle in hematological patients. Methods Sequential cohorts of 3–6 patients were recruited for each dose level starting with 600 mg/m2, a dose level already proven to be well tolerated in patients with solid tumors. Results Two dose levels 600 mg/m2/d and 900 mg/m2/d have so far been examined (3 patients each) and recruitment to the dose level 1000 mg/m2/d is ongoing. The 6 patients have each been treated with 1–3 cycles of treatment. The adverse events related to PXD101 treatment have been of grade 1–2. The most frequent were fatigue (6/9 treatment cycles), nausea (7/9 cycles), vomiting (7/9 cycles) and diarrhoea (3/9 cycles). Further safety data will be presented. So far no significant trends indicating hematological or any other systemic toxicity has been noted. Antineoplastic activity has been observed; detailed response data will be presented. ConclusionsThe novel HDAC inhibitor PXD101 is generally well tolerated in patients with previously treated hematological neoplasms. The MTD has not yet been defined and evaluation of patients at the 1000 mg/m2 dose level continues. Further studies using an oral administration of PXD101 are planned. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Topotarget Topotarget
Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study
Authors: D. Ye, H. Ahn, Y.-S. Pu, H. Weiqing, L.-P. Xie, S.-P. Huang, H.-C. Wu, L. Ma, S. Yamada, S. Noda, Y. Sun
Journal: Annals of Oncology (2016)
EXTH-15. TESEVATINIB MONOTHERAPY EFFICACY AGAINST GBM12 IS ROBUST IN VITRO BUT RELATIVELY MODEST IN THE INTRACRANIAL GBM12 MODEL, DESPITE EXCELLENT BRAIN PENETRATION
Authors: Sani Kizilbash, Karen Parrish, Janice Laramy, Minjee Kim, Gautham Gampa, Brett Carlson, Katrina Bakken, Mark Schroeder, Paul Decker, James Tonra, William Elmquist, Jann Sarkaria
Journal: Neuro-Oncology (2016)
How Long Does Wolbachia Remain on Board?
Authors: Marc Bailly-Bechet, Patricia Martins-Simões, Gergely J. Szöllősi, Gladys Mialdea, Marie-France Sagot, Sylvain Charlat
Journal: Molecular Biology and Evolution (2017)

Wolbachia bacteria infect about half of all arthropods, with diverse and extreme consequences ranging from sex-ratio distortion and mating incompatibilities to protection against viruses. These phenotypic effects, combined with efficient vertical transmission from mothers to offspring, satisfactorily explain the invasion dynamics of Wolbachia within species. However, beyond the species level, the lack of congruence between the host and symbiont phylogenetic trees indicates that Wolbachia horizontal transfers and extinctions do happen and underlie its global distribution. But how often do they occur? And has the Wolbachia pandemic reached its equilibrium? Here, we address these questions by inferring recent acquisition/loss events from the distribution of Wolbachia lineages across the mitochondrial DNA tree of 3,600 arthropod specimens, spanning 1,100 species from Tahiti and surrounding islands. We show that most events occurred within the last million years, but are likely attributable to individual level variation (e.g., imperfect maternal transmission) rather than population level variation (e.g., Wolbachia extinction). At the population level, we estimate that mitochondria typically accumulate 4.7% substitutions per site during an infected episode, and 7.1% substitutions per site during the uninfected phase. Using a Bayesian time calibration of the mitochondrial tree, these numbers translate into infected and uninfected phases of approximately 7 and 9 million years. Infected species thus lose Wolbachia slightly more often than uninfected species acquire it, supporting the view that its present incidence, estimated here slightly below 0.5, represents an epidemiological equilibrium.
MNGO-06. CLINICAL COURSE OF GRADE II MENINGIOMAS INDICATE POSSIBILITY OF OVER DIAGNOSIS
Authors: Takeo Uzuka, Ryohei Otani, Yoshihiro Abe, Hazuki Matsuda, Phyo Kim, Keisuke Ueki
Journal: Neuro-Oncology (2016)

Up to 30 % of meningiomas are diagnosed as WHO grade II based on the current WHO classification criteria. However, report on clinical prognosis of those tumors in the modern era with the technical advancement is scarce. We reviewed the clinical course and pathological findings of recent grade II meningioma cases. Adult intracranial meningioma cases from 2009 to 2014 were included in this study. All cases were histologically reviewed again and were classified as grade I or II meningiomas according to the new WHO 2016 criteria. There were 52 female and 12 male patients with ages ranging from 25 to 87 yeas (median 58). Thirty-seven were diagnosed grade I, and 27 as grade II. Seven cases were excluded due to poor sample status for histological diagnosis. Grade II tumors were divided into two subgroups; group IIa (n = 10) with increased mitosis in a localized area, and group IIb (n = 17) either with increased mitosis in several areas, satisfying soft criteria, or brain invasion. The age of grade IIb (median 69) was higher than that of grade I and IIa (median; 57 and 50, respectively). Female to male ratio in grade IIb was relatively high (29.4%). MIB-1 labeling index was also higher in grade IIb (median 10.3) than grade I and IIa (median; 3.0 and 2.1, respectively). Clinically, recurrences were observed in 6 cases; 5 in grade IIb and 1 in grade I. There were no recurrence in grade IIa cases. This study indicates that some meningioma cases diagnosed as grade II according to the WHO 2016 may have better clinical behavior than predicted. Further studies with larger cases may delineate those tumors with better prognosis and lead to refinement of the criteria.
Lecture Notes on Cardiology.
Journal: Annals of Internal Medicine (1974)

Foreword Acknowledgements Abbreviations 1 Taking a Cardiovascular History 2 Examination of the Cardiovascular System 3 Imaging 4 Hypertension 5 The Myocardium 6 Heart Failure 7 Thrombosis in Cardiovascular Disease8 Coronary Heart Disease 9 Pacing and Electrophysiology 10 Cardiopulmonary Resuscitation 11 Valvular Heart Disease 12 The Endocardium 13 The Pericardium 14 Cardiac Tumours 15 Diseases of the Aorta 16 Pulmonary Hypertension and Pulmonary Thromboembolic Disease 17 The Heart in Pregnancy 18 Congenital Heart Disease in Adults 19 Heart Disease in the Elderly 20 Cardiology, the Law and Occupation 21 Assessment for Anaesthesia Index
Pathological central review of 400 thymic epithelial tumors (TET): The national network RYTHMIC experience
Authors: T. Molina, M.V. Bluthgen, L. Chalabreysse, V. De Montpréville, A. De Muret, V. Hofman, S. Lantuejoul, M. Parrens, I. Rouquette, V. Secq, N. Girard, A. Marx, B. Besse
Journal: Annals of Oncology (2016)
Estimation of 2-Aminofluorene and Related Compounds in Biologic Material
Authors: Benton B. Westfall
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Estimation of 2-Aminofluorene and Related Compounds in Biologic Material Get access Benton B. Westfall Benton B. Westfall Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 1, August 1945, Pages 23–29, https://doi.org/10.1093/jnci/6.1.23 Published: 01 August 1945
Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)
Authors: Laurie H Sehn, Edward L G Hardy, Karamjit K Gill, Abdulwahab J Al-Tourah, Jesse Shustik, Nicol A Macpherson, Adrian Yee, Wendy Lam, Kerry J. Savage, Richard Klasa, Diego Villa, Alina S Gerrie, Tamara Shenkier, Graham W Slack, Randy D. Gascoyne, Francois Benard, Don Wilson, Peter Tonseth, Joseph M Connors
Journal: Blood (2014)
Comparison of Outcomes Between 2-Year Survivors After Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Ronald Sobecks, Robert Dean, Lisa Rybicki, Matt Kalaycio, Brad Pohlman, Steven Andresen, Edward Copelan, Shawnda Tench, Brian J. Bolwell
Journal: Blood (2009)
Compliance With A Three Month Telecoaching Program To Enhance Physical Activity In Patients With Chronic Obstructive Pulmonary Disease
Authors: Matthias Loeckx, Z Louvaris, R. J Tanner, C Yerramasu, G Buesching, A Frei, H Oosterom, Maarten Spruyt, C De Jong, E Gimeno-Santos, C Perez, R Rabinovich, I Vogiatzis, M. A Puhan, M. I Polkey, J. Garcia Aymerich, Thierry Troosters, Heleen Demeyer
Journal: American Journal of Respiratory and Critical Care Medicine (2015)
P01.04 Adult and paediatric GBM cells show differential phenotypic responses to external lipoprotein deprivation
Authors: J. Wood, D. Kim, S. Alqahtani, S. Smith, D. Barrett, R. Grundy, R. Rahman
Journal: Neuro-Oncology (2016)

polyneuropathy occurs already early in treatment after application of only 1 to 6 doses in a substantial number of patients.Toxicity of the complete treatment protocol including adjuvant chemotherapy will be analysed and presented elsewhere.
Adoptive Cellular Therapy for Follicular Lymphoma Using Genetically-Modified Autologous CD20-Specific T Cells.
Authors: Brian G. Till, Michael C. Jensen, Jinjuan Wang, Eric Y. Chen, Scott James, Andrew Raubitschek, Stephen J. Forman, Ajay K. Gopal, John M. Pagel, Catherine G. Lindgren, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press
Journal: Blood (2007)
MPTH-45. MEDULLOBLASTOMA: CANDIDATE PATHWAYS FOR NOVEL TREATMENT STRATEGIES
Authors: Tiffany Hodges, Nader Sanai, Joanne Xiu, Lyndon Kim, Shouhao Zhou, Santosh Kesari, Marta Penas-Prado, Amy Heimberger
Journal: Neuro-Oncology (2016)

Medulloblastoma, an aggressive but potentially curable CNS disease, remains a treatment challenge due to the biological heterogeneity of the disease. Analysis of actionable targets can provide opportunities in the development of curative therapies. To identify potential candidate genes, we investigated alterations in a cohort of medulloblastomas. Tumors from 36 medulloblastoma patients were profiled using immunohistochemistry, next generation sequencing, pyrosequencing, fluorescence in situ hybridization, and fragment analysis at Caris Life Sciences. Primary tumor location included the posterior fossa (n = 18) and other (n=18). There were 18 adults (9 male, 9 female, median age: 30, range: 18-47 years) and 18 pediatric patients (14 male, 4 female, median age: 7, range: 2-14 years). Medulloblastomas showed the highest expression of MRP1 (88.9%, 8/9 tumors), TUBB3 (85.7%, 18/21 tumors), PTEN (84.8%, 28/33 tumors), TOP2A (83.9%, 26/31 tumors), thymidylate synthase (TS; 80%, 24/30 tumors), RRM1 (71.4%, 15/21 tumors), and TOPO1 (63.3%, 19/30 tumors). Among them, TS expression was higher in males (94.1%, 16/17 tumors) than females (61.5%, 8/13 tumors, p=0.0397). TOP2A overexpression was much higher in posterior fossa tumors than in tumors in other locations (5/14 and 0/17, respectively, p=0.012). There was low PD-1+ T-cell infiltration (8.3%, 1/12 tumors) and no expression of PD-L1 in these tumors. Among 19 tumors sequenced, 2 had mutations in TP53 (H178fs, Q167fs) and PDE4DIP (E243fs), and one mutation occurred in each of the following: BRCA2 (V220fs/D2242fs), CTNNB1 (G34V), PIK3CA (E545G), ARID1A (I1664fs), SMO (L412F), FOXO3 (L382fs), and PTCH1 (Q694fs). Distinct molecular features in adult and pediatric medulloblastomas identified candidate pathways for further interrogation. BRCA2, PIK3CA, ARID1A, SMO, PTCH1 as well as TOP2A, TS, RRM1, and TOPO1 are among potential therapeutic targets for medulloblastoma patients.
Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma
Authors: Behnam Saberi, Alia S. Dadabhai, Christine M. Durand, Benjamin Philosophe, Andrew M. Cameron, Mark S. Sulkowski, Ahmet Gurakar
Journal: Hepatology (2017)

Saberi, Behnam; Dadabhai, Alia S.; Durand, Christine M.; Philosophe, Benjamin; Cameron, Andrew M.; Sulkowski, Mark S.; Gurakar, Ahmet Author Information
Erythrocyte Alloimmunization Analyzed by Gender and Transfusion Status
Authors: Akihiro Takeshita, Hiroko Watanabe, Harumi Fujihara, Chiaki Yamada, Machiko Oshida, Kimiko Yurugi, Yutaka Tomoda, Makoto Uchikawa, Shuichi Kino, Kenneth E Nollet, Hitoshi Ohto
Journal: Blood (2010)
Tumor Cell-Derived HLA-B-Associated Transkript 3 (BAT3) Is a Ligand for NKp30 and Activates NK Cells.
Authors: Elke Pogge von Strandmann, Venkateswara R. Simhadri, Bastian von Tresckow, Stefanie Sasse, Katrin S. Reiners, Hinrich P. Hansen, Achim Rothe, Peter Borchmann, Peter J. McKinnon, Michael Hallek, Andreas Engert
Journal: Blood (2006)
Comparison of the toxicity and response of a novel outpatient weekly CDFLEM (cisplatin, docetaxel, fluorourcil, leucovorin, epirubicin, methotrexate) induction chemotherapy versus triweekly TPF or PF in locally advanced SCCHN
Authors: J.-C. Lin, Y.-C. Liu, P.-J. Lin
Journal: Annals of Oncology (2016)
Pulmonary Function Tests and Their Correlation with Tricuspid Regurgitant Jet Velocity in Pediatric Sickle Cell Disease Patients.
Authors: Manuel Arteta, Andrew D. Campbell, Caterina Minniti, Greg Ensing, Craig Sable, Sohail Rana, D. Darbari, Onyekwere Onyinye, Greg J. Kato, Mark T. Gladwin, Oswaldo L. Castro, Victor R. Gordeuk
Journal: Blood (2007)
Abstract 347: Targeted FAK Activation in Cardiomyocytes Protects the Heart from Doxorubicin-Induced Cardiomyopathy
Authors: Zhaokang Cheng, Laura A DiMichele, Zeenat S Hakim, Mauricio Rojas, Christopher P Mack, Joan M Taylor
Journal: Circulation Research (2012)

OBJECTIVE: We recently reported that cardiac-restricted activation of focal adhesion kinase (FAK) attenuated myocardial injury following ischemia/reperfusion using transgenic mice that express a FAK variant (termed SuperFAK) in cardiomyocytes. Here we interrogated whether targeted elevation of myocardial FAK activity could protect against cardiomyopathy induced by the highly effective chemotherapy drug Doxorubicin (DOX). METHODS AND RESULTS: Eight- to twelve-week-old male mice were given a single injection of DOX (20mg/kg, i.p.). At day 14, SuperFAK mice exhibited better survival (62.5%, n=8) than littermate control mice (37.5%, n=8). Serial echocardiography revealed that DOX administration markedly decreased cardiac function and ventricular wall thickness in control mice, whereas both parameters were better preserved in SuperFAK mice at day 5 (fractional shortening: 52.7±1.5% in SuperFAK vs . 38.9±3.7% in control, p &lt;0.01; posterior wall end-systolic thickness: 1.83±0.12mm in SuperFAK vs . 1.43±0.12mm in control, p &lt;0.05). Importantly, SuperFAK hearts exhibited a dramatic increase in FAK activity (as assessed by phospho-FAK Y397 immunoblotting) and a reduction in myocyte apoptosis (as assessed by TUNEL staining) in comparison with control hearts. DOX also induced apoptosis in cultured neonatal rat cardiomyocytes and adenoviral-mediated expression of SuperFAK ameliorated DOX-induced toxicity as assessed by MTT and TUNEL assays. Over-expression of SuperFAK also enhanced expression of the pro-survival NF-κB transcriptional targets Bcl-2, Bcl-xl, and X-linked inhibitor of apoptosis, whereas pharmacologically blockade of the NF-κB pathway completely abolished the up-regulation of these anti-apoptotic molecules by SuperFAK. CONCLUSIONS: Ventricular dysfunction and myocyte apoptosis induced by DOX was attenuated by enhancing cardiac FAK activity, which may represent a novel strategy to reduce anthracycline mediated cardiotoxicity in cancer patients undergoing chemotherapy.
P08.54 Revisiting the,,go or grow” hypothesis in glioma in vivo
Authors: K. Karimian Jazi, M. Ratliff, G. Solecki, M. Osswald, E. Jung, A. Berghoff, J. Grosch, M. Bendszus, W. Wick, F. Winkler
Journal: Neuro-Oncology (2016)

It has been that tumor mesenchymal stem-like cells (tMSLCs) can be isolated from high grade gliomas and also play a part in glioma progression.Moreover, it has been reported that the success of tMSLCs isolation take a critical role in the overall survival of WHO grade IV glioma patients.Despite of these reports, not always the tMSLCs isolation from surgical specimen was successful.The weights of surgical specimens from high-grade gliomas were vary, therefore, we assessed fifty-one fresh high grade glioma specimens divide into two groups, according to success or failure of tMSLCs isolation.As a result, we found there is no significant difference in the weights of specimens in the two groups, and calculated the optimal weight of samples for tMSLCs isolation was 180mg.Furthermore, we obtained the results of no significant differences between two groups in other characteristics; patient age, sex, pathologic diagnosis, tumor types, molecular markers.Consequently, in contrast with our presumption the yield rate of tMSLCs isolation was not related to the weight of surgical specimens.P08.